Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
December 2005

Infliximab Combined With Methotrexate as Long-term Treatment for Erythrodermic Psoriasis

Author Affiliations

Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005

Arch Dermatol. 2005;141(12):1607-1610. doi:10.1001/archderm.141.12.1607

Severe erythrodermic psoriasis, unresponsive to systemic treatments, is disabling for the patient and a challenge for dermatologists. Methotrexate, cyclosporine, and acitretin have been the treatments of choice.1 However, long-term therapy with these drugs often leads to difficult complications or adverse effects. Thus, new biologic agents such as tumor necrosis factor (TNF) inhibitors provide a welcome alternative. In controlled clinical trials, infliximab has proven to be an effective and fast-acting treatment for plaque-type psoriasis.24

First Page Preview View Large
First page PDF preview
First page PDF preview